History and Perspectives of A2A Adenosine Receptor Antagonists as Potential Therapeutic Agents

Medicinal Research Reviews

Volumn 35, Issue 4, 2015, Pages 790-848

  Preti, Delia ^a   Baraldi, Pier Giovanni ^a   Moorman, Allan R ^b   Borea, Pier Andrea ^a   Varani, Katia ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b Alta Vetta Pharmaceutical Consulting LLC   (United States)

Author keywords

A2A antagonists; Human A2A adenosine receptors; Parkinson's disease; Polypharmacology

Indexed keywords

4 AMINOBUTYRIC ACID; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 6,6 BICYCLIC; 9H PURINE DERIVATIVE; ADENOSINE A2A RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; BENZOFURAN DERIVATIVE; BENZOTHIAZOLE DERIVATIVE; CAFFEINE; GLUTAMIC ACID; GUANINE NUCLEOTIDE BINDING PROTEIN; HETERODIMER; HOMODIMER; INDENOPYRIMIDINE; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; NEUROPROTECTIVE AGENT; PURINE DERIVATIVE; PYRAZINE DERIVATIVE; PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE; THIENOPYRIMIDINE; TRIAZINE DERIVATIVE; TRICYCLIC XANTHINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANTHINE DERIVATIVE; ADENOSINE A2 RECEPTOR ANTAGONIST;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ALPHA HELIX; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOLUMINESCENCE; CARBOXY TERMINAL SEQUENCE; DRUG DISTRIBUTION; FLUOROMETRY; HISTORY OF MEDICINE; HUMAN; IMMUNOPRECIPITATION; LIGAND BINDING; LOCOMOTION; MEDICINAL CHEMISTRY; MOLECULAR MODEL; MUTAGENESIS; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POLYPHARMACOLOGY; RESONANCE ENERGY TRANSFER; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; HISTORY; PRECLINICAL STUDY; PROTEIN MULTIMERIZATION;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HISTORY, 20TH CENTURY; HUMANS; PROTEIN MULTIMERIZATION; SIGNAL TRANSDUCTION;

EID: 84930587811     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21344     Document Type: Article

References (273)

1. Fredholm BB. Adenosine receptors as drug targets. Exp Cell Res 2010;316(8):1284-1288.
2. Fredholm BB, AP IJ, Jacobson KA, Linden J, Muller CE. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-an update. Pharmacol Rev 2011;63(1):1-34.
3. Chen JF, Eltzschig HK, Fredholm BB. Adenosine receptors as drug targets-what are the challenges? Nat Rev Drug Discov 2013;12(4):265-286.
4. Stone TW, Ceruti S, Abbracchio MP. Adenosine receptors and neurological disease: Neuroprotection and neurodegeneration. Handb Exp Pharmacol 2009;193:535-587.
5. Baraldi PG, Tabrizi MA, Gessi S, Borea PA. Adenosine receptor antagonists: Translating medicinal chemistry and pharmacology into clinical utility. Chem Rev 2008;108(1):238-263.
6. Muller CE, Jacobson KA. Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta 2011;1808(5):1290-1308.
7. 2A adenosine receptor antagonists in the therapy of Parkinson's disease. Pharmacol Ther 2011;132(3):280-299.
8. Ross GW, Abbott RD, Petrovitch H, White LR, Tanner CM. Relationship between caffeine intake and parkinson disease. JAMA 2000;284(11):1378-1379.
9. 2A adenosine receptor overexpression and functionality, as well as TNF-alpha levels, correlate with motor symptoms in Parkinson's disease. FASEB J 2010;24(2):587-598.
10. Gomes CV, Kaster MP, Tome AR, Agostinho PM, Cunha RA. Adenosine receptors and brain diseases: Neuroprotection and neurodegeneration. Biochim Biophys Acta 2011;1808(5):1380-1399.
11. Rivera-Oliver M, Diaz-Rios M. Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: A review. Life Sci 2014;101(1-2):1-9.
12. Fredholm BB, Arslan G, Halldner L, Kull B, Schulte G, Wasserman W. Structure and function of adenosine receptors and their genes. Naunyn Schmiedebergs Arch Pharmacol 2000;362(4-5):364-374.
13. 2A signaling. Prog Neurobiol 2007;83(5):263-276.
14. 2A receptor complex. Proteins 2010;78(1):197-211.
15. Sakagami H, Matsuya S, Nishimura H, Suzuki R, Kondo H. Somatodendritic localization of the mRNA for EFA6A, a guanine nucleotide exchange protein for ARF6, in rat hippocampus and its involvement in dendritic formation. Eur J Neurosci 2004;19(4):863-870.
16. 2A adenosine receptor mutations on agonist and antagonist binding. PLoS One 2014;9(10):e108492.
17. Salon JA, Lodowski DT, Palczewski K. The significance of G protein-coupled receptor crystallography for drug discovery. Pharmacol Rev 2011;63(4):901-937.
18. 2A receptor ligands. ChemMedChem 2011;6(12):2302-2311.
19. Boukharta L, Gutiérrez-de-Terán H, Aqvist J. Computational prediction of alanine scanning and ligand binding energetics in G-protein coupled receptors. PLoS Comput Biol 2014;10(4):e1003585.
20. 2A adenosine receptors: Involvement of glu(13) and his(278) in ligand binding and sodium modulation. Biochem Pharmacol 2000;60(5):661-668.
21. 2A adenosine receptor bound to an antagonist. Science 2008;322(5905):1211-1217.
22. 2A adenosine receptor. Science 2011;332(6027):322-327.
23. 2A receptor in complex with ZM241385 and the xanthines XAC and caffeine. Structure 2011;19(9):1283-1293.
24. Liu W, Chun E, Thompson AA, Chubukov P, Xu F, Katritch V, Han GW, Roth CB, Heitman LH, IJzerman AP, Cherezov V, Stevens RC. Structural basis for allosteric regulation of GPCRs by sodium ions. Science 2012;337(6091):232-236.
25. 2A receptor structures reveal common features of GPCR activation. Nature 2011;474(7352):521-525.
26. 2A adenosine receptor ligands. J Med Chem 2010;53(9):3748-3755.
27. 2A receptor antagonists. J Med Chem 2010;53(4):1799-1809.
28. 2A receptor as a drug discovery target. J Med Chem 2014;57(9):3623-3650.
29. Headrick JP, Ashton KJ, Rose'meyer RB, Peart JN. Cardiovascular adenosine receptors: Expression, actions and interactions. Pharmacol Ther 2013;140(1):92-111.
30. Dias RB, Rombo DM, Ribeiro JA, Henley JM, Sebastiao AM. Adenosine: Setting the stage for plasticity. Trends Neurosci 2013;36(4):248-257.
31. 2A agonists in development for the treatment of inflammation. Expert Opin Investig Drugs 2005;14(7):797-806.
32. 3 adenosine receptor up-regulation in rheumatoid arthritis patients by treatment with anti-tumor necrosis factor alpha but not methotrexate. Arthritis Rheum 2009;60(10):2880-2891.
33. 2A adenosine receptors to engineer inflammation in vivo. Int J Biochem Cell Biol 2003;35(4):410-414.
34. 2A receptor signaling and golf assembly show a specific requirement for the gamma7 subtype in the striatum. J Biol Chem 2010;285(39):29787-29796.
35. Schulte G, Fredholm BB. Signalling from adenosine receptors to mitogen-activated protein kinases. Cell Signal 2003;15(9):813-827.
36. Hasko G, Linden J, Cronstein B, Pacher P. Adenosine receptors: Therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 2008;7(9):759-770.
37. Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 2006;5(3):247-264.
38. Angers S, Salahpour A, Bouvier M. Dimerization: An emerging concept for G protein-coupled receptor ontogeny and function. Annu Rev Pharmacol Toxicol 2002;42:409-435.
39. Cavic M, Lluis C, Moreno E, Bakesova J, Canela EI, Navarro G. Production of functional recombinant G-protein coupled receptors for heteromerization studies. J Neurosci Methods 2011;199(2):258-264.
40. 2A receptors: Qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Neurochem 2004;88(3):726-734.
41. Ciruela F, Ferre S, Casado V, Cortes A, Cunha RA, Lluis C, Franco R. Heterodimeric adenosine receptors: A device to regulate neurotransmitter release. Cell Mol Life Sci 2006;63(21):2427-2431.
42. Casado V, Ferrada C, Bonaventura J, Gracia E, Mallol J, Canela EI, Lluis C, Cortes A, Franco R. Useful pharmacological parameters for G-protein-coupled receptor homodimers obtained from competition experiments. Agonist-antagonist binding modulation. Biochem Pharmacol 2009;78(12):1456-1463.
43. Sitkovsky M, Lukashev D. Regulation of immune cells by local-tissue oxygen tension: HIF1 alpha and adenosine receptors. Nat Rev Immunol 2005;5(9):712-721.
44. 2AR heteromers coupled to Gs and G i/o proteins modulate GABA transport into astrocytes. Purinergic Signal 2013;9(3):433-449.
45. Ferré S, Navarro G, Casadó V, Cortés A, Mallol J, Canela EI, Lluís C, Franco R. G protein-coupled receptor heteromers as new targets for drug development. Prog Mol Biol Transl Sci 2010;91:41-52.
46. Sheth S, Brito R, Mukherjea D, Rybak LP, Ramkumar V. Adenosine receptors: Expression, function and regulation. Int J Mol Sci 2014;15(2):2024-2052.
47. 2A and cannabinoid CB1 receptor antagonists in an animal model of Parkinson disease. J Neuropathol Exp Neurol 2014;73(5):414-424.
48. 2A receptor complexes in the striatum. Biotechniques 2011;51(2):111-118.
49. 2A receptors control cannabinoid CB1 receptor-mediated inhibition of striatal glutamatergic neurotransmission. J Neurochem 2011;116(2):273-280.
50. 2 receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: Biochemical and behavioral studies. Exp Neurol 2014;253:180-191.
51. Morin N, Di Paolo T. Interaction of adenosine receptors with other receptors from therapeutic perspective in Parkinson's disease. Int Rev Neurobiol 2014;119:151-167.
52. 2A and glutamate mGlu5 receptors: Implications for striatal neuronal function. Proc Natl Acad Sci USA 2002;99(18):11940-11945.
53. 2A receptors for Parkinson's disease. Neurotherapeutics 2009;6(1):141-151.
54. Geldenhuys WJ, Van der Schyf CJ. Rationally designed multi-targeted agents against neurodegenerative diseases. Curr Med Chem 2013;20(13):1662-1672.
55. Anighoro A, Bajorath J, Rastelli G. Polypharmacology: Challenges and opportunities in drug discovery. J Med Chem 2014;57(19):7874-7887.
56. 2A receptors: Past, present and future trends for the treatment of Parkinson's disease. Curr Med Chem 2014;21(27):3188-3210.
57. 2 receptors in rat striatal membranes. Proc Natl Acad Sci USA 1991;88(16):7238-7241.
58. 2 receptor-induced responses in stably transfected human neuroblastoma cells. J Neurochem 2000;74(1):432-439.
59. Alves G, Forsaa EB, Pedersen KF, Dreetz Gjerstad M, Larsen JP. Epidemiology of Parkinson's disease. J Neurol 2008;255(Suppl 5):18-32.
60. Fox SH. Non-dopaminergic treatments for motor control in Parkinson's disease. Drugs 2013;73(13):1405-1415.
61. Kalia LV, Brotchie JM, Fox SH. Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials. Mov Disord 2013;28(2):131-144.
62. 2A receptor antagonism reverses inflammation-induced impairment of microglial process extension in a model of Parkinson's disease. Neurobiol Dis 2014;67:191-202.
63. Chen JF. Adenosine receptor control of cognition in normal and disease. Int Rev Neurobiol 2014;119:257-307.
64. Laurent C, Eddarkaoui S, Derisbourg M, Leboucher A, Demeyer D, Carrier S, Schneider M, Hamdane M, Müller CE, Buée L, Blum D. Beneficial effects of caffeine in a transgenic model of Alzheimer's disease-like tau pathology. Neurobiol Aging 2014;35(9):2079-2090.
65. Arendash GW, Mori T, Cao C, Mamcarz M, Runfeldt M, Dickson A, Rezai-Zadeh K, Tane J, Citron BA, Lin X, Echeverria V, Potter H. Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer's disease mice. J Alzheimers Dis 2009;17(3):661-680.
66. Cao C, Cirrito JR, Lin X, Wang L, Verges DK, Dickson A, Mamcarz M, Zhang C, Mori T, Arendash GW, Holtzman DM, Potter H. Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimer's disease transgenic mice. J Alzheimers Dis 2009;17(3):681-697.
67. Chu YF, Chang WH, Black RM, Liu JR, Sompol P, Chen Y, Wei H, Zhao Q, Cheng IH. Crude caffeine reduces memory impairment and amyloid β(1-42) levels in an Alzheimer's mouse model. Food Chem 2012;135(3):2095-2102.
68. Zeitlin R, Patel S, Burgess S, Arendash GW, Echeverria V. Caffeine induces beneficial changes in PKA signaling and JNK and ERK activities in the striatum and cortex of Alzheimer's transgenic mice. Brain Res 2011;1417:127-136.
69. 2A receptor function in peripheral blood cells in Huntington's disease. FASEB J 2003;17(14):2148-2150.
70. 2A receptors in a large representation of polyglutamine disorders and Huntington's disease stages. Neurobiol Dis 2007;27(1):36-43.
71. 2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice. Neurobiol Dis 2007;28(2):197-205.
72. Pepponi R, Ferrante A, Ferretti R, Martire A, Popoli P. Region-specific neuroprotective effect of ZM241385 towards glutamate uptake inhibition in cultured neurons. Eur J Pharmacol 2009;617(1-3):28-32.
73. 2A receptor blockade in Huntington's disease mice. Neurobiol Dis 2010;37(1):99-105.
74. 2A receptors as potentially "druggable" targets in Huntington's disease. Curr Pharm Des 2008;14(15):1500-1511.
75. 2A receptor antagonist ZM241385 on amygdala-kindled seizures and progression of amygdala kindling. J Huazhong Univ Sci Technolog Med Sci 2012;32(2):257-264.
76. 2A receptor inhibition following pilocarpine-induced status epilepticus. Epilepsy Behav 2011;22(2):207-213.
77. 1 receptors. Eur J Pharmacol 2012;674(2-3):248-254.
78. 2A adenosine receptors during reperfusion: Inhibition of chemokine induction. Am J Physiol Gastrointest Liver Physiol 2004;286(2):G285-G293.
79. 2A receptor antagonist SCH 58261 reduces striatal transmitter outflow, turning behavior and ischemic brain damage induced by permanent focal ischemia in the rat. Brain Res 2003;959(2):243-250.
80. 2A receptor antagonist SCH 58261 protects from neurological deficit, brain damage and activation of p38 MAPK in rat focal cerebral ischemia. Brain Res 2006;1073-1074:470-480.
81. 2A receptor antagonism in cerebral ischemia. Neurol Res 2005;27(2):169-174.
82. Melani A, Pugliese AM, Pedata F. Adenosine receptors in cerebral ischemia. Int Rev Neurobiol 2014;119:309-348.
83. 2A receptors modulate acute injury and neuroinflammation in brain ischemia. Mediators Inflamm 2014;2014:805198.
84. 1 receptor-mediated cardioprotection. Am J Physiol Heart Circ Physiol 2011;301(3):H1183-H1189.
85. 2A receptors. Eur Heart J 2011;32(6):721-729.
86. 2B receptors to ischemic coronary dilation: Role of K(V) and K(ATP) channels. Microcirculation 2010;17(8):600-607.
87. Kumar V. Adenosine as an endogenous immunoregulator in cancer pathogenesis: Where to go? Purinergic Signal 2013;9(2):145-165.
88. Varani K, Padovan M, Govoni M, Vincenzi F, Trotta F, Borea PA. The role of adenosine receptors in rheumatoid arthritis. Autoimmun Rev 2010;10(2):61-64.
89. Zhong Y, Yang Z, Huang WC, Luo X. Adenosine, adenosine receptors and glaucoma: An updated overview. Biochim Biophys Acta 2013;1830(4):2882-2890.
90. Perez-Aso M, Fernandez P, Mediero A, Chan ES, Cronstein BN. Adenosine 2A receptor promotes collagen production by human fibroblasts via pathways involving cyclic AMP and AKT but independent of Smad2/3. FASEB J 2014;28(2):802-812.
91. 2A receptors diminishes scarring. FASEB J 2012;26(10):4254-4263.
92. 2A receptors promote collagen production by a Fli1- and CTGF-mediated mechanism. Arthritis Res Ther 2013;15(3):R58.
93. 2A receptor blockade or deletion diminishes fibrocyte accumulation in the skin in a murine model of scleroderma, bleomycin-induced fibrosis. Inflammation 2008;31(5):299-303.
94. 2A isoform) and ERalpha mediates ethanol action in MCF-7 breast cancer cells. Oncol Rep 2009;21(4):977-981.
95. 2A receptor is a unique angiogenic target of HIF-2alpha in pulmonary endothelial cells. Proc Natl Acad Sci USA 2009;106(26):10684-10689.
96. Montinaro A, Iannone R, Pinto A, Morello S. Adenosine receptors as potential targets in melanoma. Pharmacol Res 2013;76:34-40.
97. 2A adenosine receptor. Cancer Immunol Immunother 2012;61(6):917-926.
98. 2A Receptor Antagonists and Parkinson's Disease. ACS Chem Neurosci 2011;2(10):555-567.
99. Ghai G, Francis JE, Williams M, Dotson RA, Hopkins MF, Cote DT, Goodman FR, Zimmerman MB. Pharmacological characterization of CGS 15943A: A novel nonxanthine adenosine antagonist. J Pharmacol Exp Ther 1987;242(3):784-790.
100. 2A selective adenosine receptor antagonist. Br J Pharmacol 1995;115(6):1096-1102.
101. 2A receptor antagonists in Parkinson's disease: Progress in clinical trials from the newly approved Istradefylline to drugs in early development and those already discontinued. CNS Drugs 2014;28(5):455-474.
102. 2A receptor antagonists. Curr Med Chem 2014;21(34):3918-3935.
103. Pisani L, Catto M, Leonetti F, Nicolotti O, Stefanachi A, Campagna F, Carotti A. Targeting monoamine oxidases with multipotent ligands: An emerging strategy in the search of new drugs against neurodegenerative diseases. Curr Med Chem 2011;18(30):4568-4587.
104. Francis JE, Cash WD, Psychoyos S, Ghai G, Wenk P, Friedmann RC, Atkins C, Warren V, Furness P, Hyun JL, Stone GA, Desai M, Williams M. Structure-activity profile of a series of novel triazoloquinazoline adenosine antagonists. J Med Chem 1988;31(5):1014-1020.
105. 2A receptor antagonists. Eur J Med Chem 1993;28:569-576.
106. Baraldi PG, Tabrizi MA, Romagnoli R, El-Kashef H, Preti D, Bovero A, Fruttarolo F, Gordaliza M, Borea PA. Pyrazolo[4, 3-e][1, 2, 4]triazolo[1, 5-c]pyrimidines template: Organic and medicinal chemistry approach. Curr Org Chem 2006;10:259-275.
107. 3 adenosine receptor antagonists. Eur J Med Chem 2003;38(4):367-382.
108. 3 adenosine receptor modulators: Pharmacological activities and therapeutic implications. J Med Chem 2012;55(12):5676-5703.
109. 3 adenosine receptor antagonists. J Med Chem 2012;55(11):5380-5390.
110. 2A adenosine receptor antagonist. J Pharmacol Exp Ther 1996;276(2):398-404.
111. 2A adenosine receptor antagonists. Bioorg Med Chem Lett 1994;4:2539-2544.
112. 2A adenosine antagonists. J Med Chem 1996;39(5):1164-1171.
113. 2A adenosine receptor antagonist, to rat striatal membranes. Br J Pharmacol 1996;117(7):1381-1386.
114. 2A receptor system using positron emission tomography. J Med Chem 2000;43(23):4359-4362.
115. 2A receptor-selective antagonists. Bioorg Med Chem Lett 2010;20(19):5690-5694.
116. 2A receptors with positron emission tomography. J Med Chem 2014;57(15):6765-6780.
117. 2A adenosine receptor antagonists. J Med Chem 1998;41(12):2126-2133.
118. 2A adenosine receptor antagonists: A study on the importance of modifications at the side chain on the activity and solubility. J Med Chem 2002;45(1):115-126.
119. 2 dopamine receptor agonists. Synapse 2008;62(5):345-351.
120. 2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions. Exp Neurol 2004;189(1):182-188.
121. 2A receptor antagonists: Arylpiperazine derivatives of pyrazolo[4, 3-e]-1, 2, 4-triazolo[1, 5-c]pyrimidines. Bioorg Med Chem Lett 2007;17(5):1376-1380.
122. 2A receptor antagonist for Parkinson's disease. Future Neurology 2013;8(6):638-648.
123. 2A receptor antagonists. Patent WO 2001092264.
124. Kuo S-C, Tran LT, Zhang P. Process for preparing substituted 5-amino-pyrazolo-[4, 3-e]-1, 2, 4-triazolo[1, 5-c] pyrimidines. Patent WO 2005054245.
125. 2A receptor antagonists. Bioorg Med Chem Lett 2008;18(14):4199-4203.
126. 2A receptor antagonists. Bioorg Med Chem Lett 2008;18(14):4204-4209.
127. 2A antagonists. Bioorg Med Chem Lett 2007;17(6):1659-1662.
128. Barawkar D, Basu S, Ramdas V, Naykodi M, Patel M, Shejul Y, Thorat S, Panmand A. Preparation of fused tricyclic compounds as therapeutic adenosine receptor antagonist. Patent WO 2012038980.
129. 2A receptor antagonists. Patent WO 2008121748.
130. Baraldi PG, Saponaro G, Aghazadeh Tabrizi M, Baraldi S, Romagnoli R, Moorman AR, Varani K, Borea PA, Preti D. Pyrrolo- and pyrazolo-[3, 4-e][1, 2, 4]triazolo[1, 5-c]pyrimidines as adenosine receptor antagonists. Bioorg Med Chem 2012;20(2):1046-1059.
131. 2A receptor antagonists. Bioorg Med Chem 2010;18(7):2491-2500.
132. 2A receptor antagonist. Neurosci Lett 2014;558:203-207.
133. 2A receptor antagonists: 1, 2, 4-Triazolo[1, 5-c]pyrimidines. Bioorg Med Chem Lett 2009;19(3):967-971.
134. 2A receptor antagonists: [1, 2, 4]-Triazolo[4, 3-c]pyrimidin-3-ones. Bioorg Med Chem Lett 2011;21(8):2497-2501.
135. 2A receptor antagonists. Patent WO 2011060207.
136. 1 receptor antagonists for the treatment of Parkinson's disease. J Med Chem 2012;55(3):1402-1417.
137. 1 antagonists. Bioorg Med Chem Lett 2010;20(9):2864-2867.
138. 2A receptor antagonists. Patent WO 2011053509.
139. 2A receptor antagonists. Patent WO 2011053511.
140. 1 receptor antagonist in animal models of Parkinson's disease. J Med Chem 2010;53(22):8104-8115.
141. 1 antagonists. Bioorg Med Chem Lett 2010;20(9):2868-2871.
142. 2A receptor antagonists. Patent WO 2009055548.
143. 1 antagonist with efficacy in preclinical models of Parkinson's disease. ACS Chem Neurosci 2014;5(10):1005-1019.
144. Koch P, Akkari R, Brunschweiger A, Borrmann T, Schlenk M, Kuppers P, Kose M, Radjainia H, Hockemeyer J, Drabczynska A, Kiec-Kononowicz K, Muller CE. 1, 3-Dialkyl-substituted tetrahydropyrimido[1, 2-f]purine-2, 4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases. Bioorg Med Chem 2013;21(23):7435-7452.
145. Brunschweiger A, Koch P, Schlenk M, Pineda F, Kuppers P, Hinz S, Kose M, Ullrich S, Hockemeyer J, Wiese M, Heer J, Muller CE. 8-Benzyltetrahydropyrazino[2, 1-f]purinediones: Water-soluble tricyclic xanthine derivatives as multitarget drugs for neurodegenerative diseases. Chem Med Chem 2014;9(8):1704-1724.
146. Stocchi F, Rabey JM. Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease. Eur J Neurol 2011;18(12):1373-1378.
147. 2 antagonists. J Med Chem 1992;35(12):2342-2345.
148. 2B receptor. J Med Chem 2001;44(2):170-179.
149. Jacobson KA, Gallo-Rodriguez C, Melman N, Fischer B, Maillard M, van Bergen A, van Galen PJ, Karton Y. Structure-activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists. J Med Chem 1993;36(10):1333-1342.
150. 2A-selective adenosine receptor antagonists. J Med Chem 2000;43(3):440-448.
151. 2A receptor antagonist MSX2. Molecules 2008;13(2):348-359.
152. Nonaka Y, Shimada J, Nonaka H, Koike N, Aoki N, Kobayashi H, Kase H, Yamaguchi K, Suzuki F. Photoisomerization of a potent and selective adenosine A2 antagonist, (E)-1, 3-dipropyl-8-(3, 4-dimethoxystyryl)-7-methylxanthine. J Med Chem 1993;36(23):3731-3733.
153. 2A adenosine receptor antagonists with 8-styrylxanthine structure: Potential drugs for Parkinson's disease. J Org Chem 2004;69(10):3308-3318.
154. Thomas R, Lee J, Chevalier V, Sadler S, Selesniemi K, Hatfield S, Sitkovsky M, Ondrechen MJ, Jones GB. Design and evaluation of xanthine based adenosine receptor antagonists: Potential hypoxia targeted immunotherapies. Bioorg Med Chem 2013;21(23):7453-7464.
155. 2A adenosine receptor antagonists and their preparation, pharmaceutical compositions and use in the treatment of diseases. Patent WO 2008070529.
156. 2A adenosine receptor possess bronchospasmolytic activity. Eur J Med Chem 2014;75:327-335.
157. 2A receptor by (E, E)-8-(4-phenylbutadien-1-yl)caffeine analogues. Bioorg Med Chem 2008;16(18):8676-8684.
158. 2A receptor antagonists. Bioorg Med Chem 2003;11(7):1299-1310.
159. 2A receptor antagonist (E)-8-(3-chlorostyryl)caffeine (CSC). Bioorg Med Chem 2006;14(10):3512-3521.
160. 2A antagonists/MAO-B inhibitors. J Med Chem 2013;56(3):1247-1261.
161. 2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization. J Med Chem 2005;48(22):6887-6896.
162. 2A receptor and their use as medicaments. Patent WO 2010106145.
163. 2A receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets. Eur J Pharmacol 2006;546(1-3):82-87.
164. 2A antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats. Brain Res 2007;1133(1):110-114.
165. 2A receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease. Synapse 2011;65(3):181-188.
166. 2A adenosine receptor for the treatment of Parkinson's disease. J Med Chem 2013;56(13):5456-5463.
167. 2A adenosine antagonists. Bioorg Med Chem Lett 2005;15(8):2119-2122.
168. 2A receptor antagonists for the treatment of Parkinson's disease. Neurology 2003;61(11 Suppl 6):S101-S106.
169. 2A receptor. Part 3: Design and synthesis of pyrazolo[3, 4-d]pyrimidines, pyrrolo[2, 3-d]pyrimidines and 6-arylpurines. Bioorg Med Chem Lett 2008;18(9):2924-2929.
170. Gillespie RJ, Lerpiniere J, Dawson CE, Gaur S, Pratt RM, Stratton GC, Weiss SM. Preparation of purine derivatives as purinergic receptor antagonists. Patent WO 2002055521.
171. 2A adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4, 5-d]pyrimidines. J Med Chem 2009;52(1):33-47.
172. Guckian KM, Kumaravel G. Purine receptor antagonists for treating movement disorders. Patent WO 2011050160.
173. Gillespie RJ, Lerpiniere J, Gaur S, Bamford SJ, Stratton GC, Leonardi S, Weiss SM. Preparation of triazolo[4, 5-d] pyrimidines as purinergic receptor antagonists. Patent WO 2002055083.
174. Bamford SJ, Gillespie RJ, Todd RS. Triazolo[4, 5-d] pyramidine derivatives, their preparation, and use as purine receptor antagonists for treating movement disorders and other diseases. Patent WO 2009156737.
175. 2A receptor antagonists. Bioorg Med Chem Lett 2009;19(5):1399-1402.
176. 2A adenosine receptor antagonists. Bioorg Med Chem 2014;22(12):3072-3082.
177. 9-propargyladenine derivatives as therapeutic agents for Parkinsonian syndromes. Patent WO 2012070601.
178. 2A adenosine receptors. Molecular modeling and pharmacological studies. Eur J Med Chem 2014;84:614-627.
179. 2A receptor antagonists: Comparison of three core heterocycles. Bioorg Med Chem Lett 2004;14(19):4831-4834.
180. 2A receptor antagonists. J Med Chem 2004;47(17):4291-4299.
181. 2A receptor antagonists. Bioorg Med Chem Lett 2004;14(19):4835-4838.
182. 2A receptor antagonists. J Med Chem 2005;48(6):2009-2018.
183. 2A receptor antagonists. J Med Chem 2004;47(25):6218-6229.
184. 2A adenosine receptor antagonists with improved water solubility. J Med Chem 2011;54(3):877-889.
185. 2A adenosine receptor antagonist as a potential anti-Parkinson multitarget approach. Mol Pharm 2012;9(3):591-604.
186. 2 receptor heteromers. J Med Chem 2009;52(18):5590-5602.
187. 2A adenosine receptor antagonists. Bioorg Med Chem Lett 2005;15(3):511-515.
188. 2Aadenosine receptors. Bioorg Med Chem 2000;8(11):2581-2590.
189. Federico S, Ciancetta A, Porta N, Redenti S, Pastorin G, Cacciari B, Klotz KN, Moro S, Spalluto G. Scaffold decoration at positions 5 and 8 of 1, 2, 4-triazolo[1, 5-c]pyrimidines to explore the antagonist profiling on adenosine receptors: A preliminary structure-activity relationship study. J Med Chem 2014;57(14):6210-6225.
190. 2A receptor antagonists. Med Chem Commun 2011;2:950-956.
191. 2A receptor antagonists. Patent WO 2010045006.
192. 2A receptor antagonists. Patent WO 2010045017.
193. 2A receptor antagonists. Bioorg Med Chem Lett 2013;23(9):2688-2691.
194. 2A receptor antagonists. Patent WO 2010045013.
195. 2A receptor. Part 1: Discovery and synthesis of thieno[3, 2-d]pyrimidine-4-methanone derivatives. Bioorg Med Chem Lett 2008;18(9):2916-2919.
196. Gillespie RJ, Lerpiniere J, Dawson CE, Gaur S, Pratt RM. Preparation of thieno[3, 2-d]pyrimidines and furano[3, 2-d]pyrimidines as purinergic receptor antagonists. Patent WO 2002055524.
197. 2A receptor. Part 2: Design and synthesis of 4-arylthieno[3, 2-d]pyrimidine derivatives. Bioorg Med Chem Lett 2008;18(9):2920-2923.
198. 2A receptor antagonists. Naunyn Schmiedebergs Arch Pharmacol 2007;375(2):133-144.
199. 2A receptor antagonists: Synthesis and structure-activity relationships of novel benzofuran derivatives. Bioorg Med Chem Lett 2010;20(3):1090-1093.
200. 2A receptor antagonists. Part II: Synthesis and structure-activity relationships of novel benzofuran derivatives. Bioorg Med Chem Lett 2010;20(12):3768-3771.
201. Nakamura T, Shiohara H, Terao Y, Nakayama S, Miyazawa K, Ohnota H. Novel benzofuran derivative, medicinal composition containing the same, and uses of these. Patent WO 2005073210.
202. 2A receptor antagonists. Patent WO 2006137350.
203. 2A adenosine receptor. Patent WO 2001097786.
204. Flohr A, Jakob-Roetne R, Norcross RD, Riemer C. Preparation of ureidobenzothiazoles as adenosine receptor ligands. Patent WO 2003049741.
205. 2A receptor antagonist. Patent US 20050261289.
206. 3 receptors. Patent US 20050065151.
207. Norcross RD. Preparation of benzoxazole derivatives as adenosine receptor ligands. Patent WO 2004063177.
208. Woiwode T, Moran M. 4-Hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide for the treatment of post-traumatic stress disorder. Patent WO 2009015236.
209. Perez-Lloret S, Merello M. Two new adenosine receptor antagonists for the treatment of Parkinson's disease: Istradefylline versus tozadenant. Expert Opin Pharmacother 2014;15(8):1097-1107.
210. 2A receptor antagonists. Bioorg Med Chem Lett 2010;20(3):1214-1218.
211. Mayer S, Schann S. Preparation of imidazole- based compounds as therapeutic adenosine receptor ligands. Patent WO 2010084425.
212. Gutschow M, Schlenk M, Gab J, Paskaleva M, Alnouri MW, Scolari S, Iqbal J, Muller CE. Benzothiazinones: A novel class of adenosine receptor antagonists structurally unrelated to xanthine and adenine derivatives. J Med Chem 2012;55(7):3331-3341.
213. 2A receptors and monoamine oxidase B by 4H-3, 1-benzothiazin-4-ones. J Med Chem 2013;56(11):4580-4596.
214. 2A receptor antagonists by virtual screening. J Med Chem 2012;55(5):1904-1909.
215. 2A receptor. Med Chem Commun 2014;5:571-575.
216. 2A receptor antagonists. Patent WO 2009111442.
217. 2A adenosine receptor antagonists. J Med Chem 2008;51(15):4449-4455.
218. 2A receptor antagonists with in vivo efficacy. J Med Chem 2008;51(3):400-406.
219. 2A receptor antagonists. Patent WO 2008116185.
220. Lanier MC, Slee DH, Luo Z, Lin E, Chen Y, Moorjani M, Vong BG, Tellew J. Substituted pyrimidines as adenosine receptor antagonists. Patent WO 2008070661.
221. 2A receptor antagonists: 1. Structure-activity relationships and optimization of heterocyclic substituents. J Med Chem 2008;51(6):1719-1729.
222. 2A receptor antagonists: 2. Reduction of hERG activity, observed species selectivity, and structure-activity relationships. J Med Chem 2008;51(6):1730-1739.
223. 2A antagonists with reduced hERG liability. Bioorg Med Chem Lett 2008;18(4):1269-1273.
224. 2A receptor antagonists. Bioorg Med Chem Lett 2008;18(6):1778-1783.
225. 2A antagonists with improved solubility and metabolic stability. Bioorg Med Chem Lett 2008;18(20):5402-5405.
226. 2A adenosine receptor antagonists for the treatment of Parkinson's disease. J Med Chem 2008;51(22):7099-7110.
227. 2A receptor antagonists with improved drug like properties and in vivo efficacy. J Med Chem 2009;52(3):709-717.
228. 2A receptor antagonists. Bioorg Med Chem Lett 2014;24(1):152-155.
229. 2A receptor antagonists for the treatment of Parkinson's Disease. ACS Chem Neurosci 2014;5(8):674-682
230. 2A receptor. Part 6: Further optimization of pyrimidine-4-carboxamides. Bioorg Med Chem 2009;17(18):6590-6605.
231. 2A receptor. Part 5: Highly bio-available pyrimidine-4-carboxamides. Bioorg Med Chem Lett 2009;19(10):2664-2667.
232. 2A receptor antagonists. Patent WO 2011121418.
233. Carlsson J, Tosh DK, Phan K, Gao ZG, Jacobson KA. Structure-activity relationships and molecular modeling of 1, 2, 4-triazoles as adenosine receptor antagonists. ACS Med Chem Lett 2012;3(9):715-720.
234. 2A antagonists using structure based drug design. J Med Chem 2012;55(5):1898-1903.
235. 2A receptor inhibitors useful in the treatment of diseases. Patent WO 2011095625.
236. 2A receptor antagonists and their pharmaceutical compositions. Patent WO 2005040151.
237. 2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition. J Pharmacol Exp Ther 2007;323(2):708-719.
238. 2A receptor antagonist, ASP5854, in rhesus monkeys: Relationship to anticataleptic effect. J Nucl Med 2008;49(7):1183-1188.
239. 2A receptor antagonist ASP5854 ameliorates motor impairment in MPTP-treated marmosets: Comparison with existing anti-Parkinson's disease drugs. Behav Brain Res 2008;194(2):152-161.
240. Kase J, Kanda T. Preparation of thiazole derivatives for the treatment of anxiety disorders. Patent WO 2011027806.
241. 2A receptor inhibitors for the treatment of cardiovascular diseases. Patent WO 2009015776.
242. 2A receptor antagonist. J Med Chem 2011;54(3):751-764.
243. 2 receptor blockade. Pharmacol Biochem Behav 2012;100(3):498-505.
244. Tarazi FI, Sahli ZT, Wolny M, Mousa SA. Emerging therapies for Parkinson's disease: From bench to bedside. Pharmacol Ther 2014;144(2):123-133.
245. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006; 5(6):525-535.
246. Schapira AH, Bezard E, Brotchie J, Calon F, Collingridge GL, Ferger B, Hengerer B, Hirsch E, Jenner P, Le Novere N, Obeso JA, Schwarzschild MA, Spampinato U, Davidai G. Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov 2006;5(10):845-854.
247. Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Damier P, De Yebenes J, Gershanik O, Guttman M, Grandas F, Hallett M, Hornykiewicz O, Jenner P, Katzenschlager R, Langston WJ, LeWitt P, Melamed E, Mena MA, Michel PP, Mytilineou C, Obeso JA, Poewe W, Quinn N, Raisman-Vozari R, Rajput AH, Rascol O, Sampaio C, Stocchi F. Levodopa in the treatment of Parkinson's disease: Current controversies. Mov Disord 2004;19(9):997-1005.
248. Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005;20(5):523-539.
249. Dungo R, Deeks ED. Istradefylline: First global approval. Drugs 2013;73(8):875-882.
250. 2A receptor antagonist treatment of Parkinson's disease. Neurology 2003;61(3):293-296.
251. 2A receptor antagonist istradefylline (KW6002) reduces "off" time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol 2008;63(3):295-302.
252. Mizuno Y, Hasegawa K, Kondo T, Kuno S, Yamamoto M. Clinical efficacy of istradefylline (KW6002) in Parkinson's disease: A randomized, controlled study. Mov Disord 2010;25(10):1437-1443.
253. 2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease. Mov Disord 2013;28(8):1138-1141.
254. Pourcher E, Fernandez HH, Stacy M, Mori A, Ballerini R, Chaikin P. Istradefylline for Parkinson's disease patients experiencing motor fluctuations: Results of the KW6002-US-018 study. Parkinsonism Relat Disord 2012;18(2):178-184.
255. Fernandez HH, Vanagunas A, Odin P, Espay AJ, Hauser RA, Standaert DG, Chatamra K, Benesh J, Pritchett Y, Hass SL, Lenz RA. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: Interim results. Parkinsonism Relat Disord 2013;19(3):339-345.
256. Factor S, Mark MH, Watts R, Struck L, Mori A, Ballerini R, Sussman NM. A long-term study of istradefylline in subjects with fluctuating Parkinson's disease. Parkinsonism Relat Disord 2010;16(6):423-426.
257. 2A receptor antagonists for Parkinson's disease. Expert Opin Investig Drugs 2009;18(11):1619-1631.
258. 2A receptor antagonist ST1535: Acute and subchronic studies in rats. Eur J Pharmacol 2007;566(1-3):94-102.
259. 2A adenosine receptor antagonist. Int J Neuropsychopharmacol 2006;9(5):575-584.
260. 2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease. Synapse 2007;61(8):606-614.
261. Hauser RA. Future treatments for Parkinson's disease: Surfing the PD pipeline. Int J Neurosci 2011;121(Suppl 2):53-62.
262. 2A antagonist SYN115 in Parkinson disease. J Neurosci 2010;30(48):16284-16292.
263. Hauser RA, Olanow CW, Kieburtz Neale A, Resburg C, Maya U, Bandak S. A Phase 2, placebo-controlled, randomized, double-blind trial of tozadenant (SYN-115) in patients with Parkinson's disease with wearing-off fluctuations on levodopa. Mov Disord 2013;28:S158.
264. 2A receptor antagonist BIIB014 in healthy volunteers. Mov Disord 2010;25:S298.
265. 2A brain receptor occupancy of vipadenant (BIIB014) at steady-state levels in healthy male volunteers. Clin Neuropharmacol 2010;33(2):55-60.
266. Cutler DL, Tendolkar A, Grachev ID. Safety, tolerability and pharmacokinetics after single and multiple doses of preladenant (SCH420814) administered in healthy subjects. J Clin Pharm Ther 2012;37(5):578-587.
267. 2A receptor antagonist, is not associated with QT/QTc prolongation. Eur J Clin Pharmacol 2013;69(10):1761-1767.
268. Factor SA, Wolski K, Togasaki DM, Huyck S, Cantillon M, Ho TW, Hauser RA, Pourcher E. Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease. Mov Disord 2013;28(6):817-820.
269. 2A adenosine receptor antagonists and synthesis and uses thereof. Patent WO 2013058681.
270. 2A receptor antagonists as positron emission tomography (PET) tracers. Curr Med Chem 2013;21(3):312-328.
271. 2A receptor PET tracer. J Nucl Med 2014;55(Suppl 1):356.
272. Barret O, Hannestad J, Alagille D, Vala C, Tavares A, Papin C, Morley T, Fowles K, Lee H, Seibyl J, Tytgat D, Laruelle M, Tamagnan G. Adenosine 2A receptor occupancy by tozadenant and preladenant in rhesus monkeys. J Nucl Med 2014;55(10):1712-1718.
273. 2A and dopamine D2 receptors for the potential treatment of parkinson's disease. J Med Chem 2015;58(2):718-738.